China to offer Covid vaccine to children as young as 3

China first country to approve jabs for young children

Leonie Chao-Fong
Tuesday 08 June 2021 13:27 BST
Comments
Children between the age of three and 17 can now receive the Sinovac vaccine
Children between the age of three and 17 can now receive the Sinovac vaccine (Copyright 2021 The Associated Press. All rights reserved)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

China has approved the emergency use of a coronavirus vaccine made by Beijing-based pharmaceutical company Sinovac for children as young as three, becoming the first country to offer jabs to young children.

Children between the age of three and 17 can now receive the Sinovac vaccine, the drugmaker has confirmed.

Early phase trials of the vaccine have been completed on children and adolescents with results to be published shortly in the Lancet scientific journal, a spokesperson for Sinovac said.

“In recent days, the Sinovac vaccine was approved for emergency use in three- to 17-year-olds,” they told AFP news agency.

The Sinovac jab will be rolled out to young children “according to China’s current epidemic prevention and control needs and vaccine supply” as determined by the National Health Commission, they added.

The World Health Organisation last week approved the Sinovac vaccine despite some gaps in the available trial data.

In a statement, the UN health agency said that it recommends the vaccine for use in adults 18 years and older and that efficacy results showed the vaccine prevented symptomatic disease in 51 per cent of those fully vaccinated.

But it could not estimate the vaccine efficacy in people over 60, as there were few older adults enrolled in clinical trials.

China’s other WHO-approved vaccine, Sinopharm, has not confirmed whether its jab has been approved for use in children.

In the UK, the vaccine developed by Pfizer has received approval for use in children aged 12 to 15 by Britain’s medicines regulator.

According to the Medicines and Healthcare products Regulatory Agency (MHRA), the jab has been proven to be safe and highly effective in that age group.

The Department of Health and Social Care said the government has now asked the JCVI to “advise whether routine vaccination should be offered to younger people aged 12 to 17”.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in